Siemionow Maria, Nasir Serdar
Department of Plastic and Reconstructive Surgery, Cleveland Clinic, Cleveland, OH 44195, USA.
Ann Plast Surg. 2008 Apr;60(4):455-62. doi: 10.1097/SAP.0b013e3180db2765.
Composite tissue allotransplants (CTA) involves transplantation of various tissues including vessels, nerves, skin, and immune cells and bears significant antigenic load. Different immunosuppressive protocols are used for experimental and clinical CTA. Immunosuppressive agents maintain survival of the different components of composite tissue allografts. However, the potential side effects of chronic immunosuppression currently limit the widespread application of CTA transplants. Bone marrow therapy in many tolerance induction protocols therefore provides a guide to reaching the target of permanent immunotolerance. Multiple studies suggest that bone marrow is immunomodulatory and may facilitate allograft acceptance. In this review, bone marrow-based therapy protocols of experimental and clinical models are presented in composite tissue transplantation.
复合组织同种异体移植（CTA）涉及包括血管、神经、皮肤和免疫细胞在内的各种组织的移植，并且具有显著的抗原负荷。不同的免疫抑制方案用于实验性和临床CTA。免疫抑制剂维持复合组织同种异体移植物不同成分的存活。然而，慢性免疫抑制的潜在副作用目前限制了CTA移植的广泛应用。因此，许多耐受诱导方案中的骨髓治疗为实现永久免疫耐受的目标提供了指导。多项研究表明，骨髓具有免疫调节作用，可能促进同种异体移植物的接受。在本综述中，介绍了复合组织移植中基于骨髓的实验和临床模型治疗方案。
